Multispecific antibodies targeting her3 and trop2 and conjugates thereof

CN122459461APending Publication Date: 2026-07-24JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD
Filing Date
2024-12-26
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

There are no multispecific antibodies or antigen-binding fragments that target HER3 and TROP2 simultaneously in the prior art, and no antibody-drug conjugates against these two targets, resulting in insufficient targeting and effectiveness of cancer treatment.

Method used

A multispecific antigen-binding protein containing HER3 binding protein was developed, which binds TROP2 and HER3 and is coupled to cytotoxins to form an antibody-drug conjugate to enhance the tumor treatment window.

Benefits of technology

By simultaneously targeting HER3 and TROP2, the killing effect of antibody drug conjugates on tumor cells is enhanced, the treatment window is improved, and the side effects on normal cells are reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000063_0000
    Figure 00000063_0000
  • Figure 00000063_0001
    Figure 00000063_0001
  • Figure 00000064_0000
    Figure 00000064_0000
Patent Text Reader

Abstract

The present application provides a HER3 single-domain antibody, a multispecific antigen binding protein and a protein-drug conjugate comprising the single-domain antibody, and use thereof in the preparation of a medicament for treating / preventing tumors.
Need to check novelty before this filing date? Find Prior Art